Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi最新文献

{"title":"[Pancreatic atrophy and pancreatic exocrine insufficiency after allogeneic hematopoietic stem cell transplantation: a case report and literature review].","authors":"Y Shan, P P Ye, R Z Pei, D Chen, T T Wang, X W Shi, Y Lu","doi":"10.3760/cma.j.cn121090-20251203-00566","DOIUrl":"10.3760/cma.j.cn121090-20251203-00566","url":null,"abstract":"<p><p>A 60-year-old male patient with acute B-cell lymphoblastic leukemia received allogeneic hematopoietic stem cell transplantation from an unrelated donor. He was transplanted with 6.22×10(8) mononuclear cells/kg and 6.27×10(6) CD34(+) cells/kg, and engraftment was confirmed at +11 days. Eighteen months post-transplant, the patient developed persistent diarrhea and continued weight loss, which was unresponsive to antidiarrheal, immunosuppressive, and antimicrobial treatments. After abdominal CT, pancreatic magnetic resonance imaging, and fecal elastase-1 tests, he was diagnosed with pancreatic atrophy and severe pancreatic exocrine insufficiency. Symptoms significantly improved following pancreatic enzyme replacement therapy.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 6","pages":"592-596"},"PeriodicalIF":0.0,"publicationDate":"2026-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical analysis of 3 cases of childhood primary pure erythroid leukemia and literature review].","authors":"D X Zhong, J J Li, L Zhang, Z X Zhang, J H Li, M Z Hu, R Liu","doi":"10.3760/cma.j.cn121090-20251109-00515","DOIUrl":"10.3760/cma.j.cn121090-20251109-00515","url":null,"abstract":"<p><p>This study aimed to investigate the clinical characteristics of primary pure erythroid leukemia (PEL) in children, particularly PEL with NFIA::CBFA2T3 or NFIA::RUNX1T1 fusions. We retrospectively analyzed clinical data from three children with PEL who were treated at the Capital Center for Children's Health, Capital Medical University, between September 2017 and September 2021, and reviewed the literature. All three patients had cytogenetic alterations: case 1 had t (1;16) (p32;q24), case 2 had an NFIA::CBFA2T3 fusion, and case 3 had an NFIA::RUNX1T1 fusion. All three patients responded poorly to standard intensive chemotherapy for acute myeloid leukemia (AML) and to regimens containing hypomethylating agents. Cases 1 and 3 died after continued disease progression. Case 2 underwent intensive chemotherapy followed by umbilical cord blood stem cell transplantation, relapsed 2 months after transplantation, and died soon thereafter. These findings suggest that primary PEL in children is characterized by an insidious onset, rapid progression, and poor response to commonly used AML chemotherapy regimens, and that patients may benefit from hematopoietic stem cell transplantation after achieving complete remission.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 6","pages":"587-591"},"PeriodicalIF":0.0,"publicationDate":"2026-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13586695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Efficacy and safety of a JAK1 inhibitor for relapsed/refractory large granular lymphocytic leukemia].","authors":"L Z Tian, L L Zhang, R N Li, W W Li, W Y Wang, J Y Zhao, J P Li, N Nie, X X Li, J Zhang, J Shi","doi":"10.3760/cma.j.cn121090-20260306-00120","DOIUrl":"10.3760/cma.j.cn121090-20260306-00120","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the efficacy and safety of monotherapy with the JAK1 inhibitor golidocitinib in patients with relapsed/refractory large granular lymphocytic leukemia (LGLL) . <b>Methods:</b> We retrospectively analyzed 16 patients with relapsed/refractory LGLL who received oral golidocitinib monotherapy at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, between January and December 2025 (13 with T-LGLL and 3 with NK-LGLL). The starting dose was 0.15 g once daily, and efficacy and safety were evaluated. <b>Results:</b> The median age was 58 years (range, 26-76 years). At baseline, the median HGB level was 58.5 g/L (range, 43.0-101.0), the median absolute neutrophil count was 1.04×10(9)/L (range, 0.02-4.18), the median absolute lymphocyte count was 1.59×10(9)/L (range, 0.38-7.20), and the median absolute large granular lymphocyte count was 0.60×10(9)/L (range, 0.06-3.63). Six patients had secondary pure red cell aplasia. With a median follow-up of 4.0 (0.8-11.1) months, the overall hematologic response rate was 87.5% (14/16), with a median time to hematologic response of 2.9 (1.4-7.6) weeks. The complete hematologic response rate was 43.8% (7/16). The incidence of drug-associated adverse events (DAE) was 75.0% (12/16). Five patients experienced grade 3 adverse events, including grade 3 neutropenia in 2 cases, grade 3 thrombocytopenia in 2 cases, and grade 3 elevation of aspartate aminotransferase in 1 case. All remaining DAEs were grade 1-2. <b>Conclusion:</b> Golidocitinib monotherapy showed activity in patients with relapsed/refractory LGLL, with a rapid onset of response and a manageable short-term safety profile.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 6","pages":"571-575"},"PeriodicalIF":0.0,"publicationDate":"2026-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Mechanism and clinical progress of JAK inhibitors in hemophagocytic lymphohistiocytosis].","authors":"M X Wang, Y Z Zhao, Z G Li, T Y Wang, R Zhang","doi":"10.3760/cma.j.cn121090-20251209-00578","DOIUrl":"10.3760/cma.j.cn121090-20251209-00578","url":null,"abstract":"<p><p>Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome characterized by uncontrolled activation of lymphocytes and macrophages. Owing to its marked etiological heterogeneity, HLH is broadly classified into primary and secondary forms. Janus kinase (JAK) inhibitors, represented by ruxolitinib, exert therapeutic effects by blocking the JAK-STAT signaling pathway and suppressing the secretion of various cytokines, including interferon-γ. Accumulating evidence suggests that JAK inhibitors demonstrate unique therapeutic potential across diverse etiological backgrounds of HLH. This review summarizes the mechanisms and clinical research progress of JAK inhibitors in the treatment of HLH.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 6","pages":"611-616"},"PeriodicalIF":0.0,"publicationDate":"2026-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[CD20-negative/CD10-positive mantle cell lymphoma (blastic variant): a case report].","authors":"B B Qiao, Y X Ning, J Hao, C L Shi, D Liu, K Dong, Y F Zhang, J M Chang, F G Ren, H W Wang, Z F Xu","doi":"10.3760/cma.j.cn121090-20251223-00610","DOIUrl":"10.3760/cma.j.cn121090-20251223-00610","url":null,"abstract":"","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 6","pages":"603"},"PeriodicalIF":0.0,"publicationDate":"2026-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Comparative study of the prognostic value of survival prognostic scoring systems in patients with essential thrombocythemia: IPSET, MIPSS-ET, AAA, and AAA].","authors":"S Y Zhao, Z F Xu, T J Qin, B Li, S Q Qu, Q Sun, Y J Jia, C W Li, L J Pan, Q Y Gao, M Jiao, Z F Bao, Z J Xiao","doi":"10.3760/cma.j.cn121090-20260131-00072","DOIUrl":"10.3760/cma.j.cn121090-20260131-00072","url":null,"abstract":"<p><p><b>Objective:</b> To validate and compare the applicability of the international prognostic score for ET (IPSET), the mutation-enhanced international prognostic systems for ET (MIPSS-ET), triple A (AAA), and triple A plus (AAA+) survival prognostic scoring systems in Chinese patients with essential thrombocythemia (ET) . <b>Methods:</b> In this external validation and comparative study of clinical prediction models, 423 patients with ET who visited the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College between January 2015 and December 2022 were retrospectively analyzed. Risk stratification was performed using the IPSET, MIPSS-ET, AAA, and AAA+ survival prognostic scoring systems. Harrell's concordance index (C-index), Brier score, net reclassification improvement (NRI), and integrated discrimination improvement (IDI) were used to comprehensively evaluate and compare the predictive discrimination, calibration, and risk restratification efficacy of each model for overall survival (OS) . <b>Results:</b> The median age at diagnosis of the enrolled patients was 50 years [interquartile range (<i>IQR</i>) : 34-62], and 60.8% (257 cases) were female. Overall, 22.0% (93 cases) of the patients had a history of thrombosis prior to diagnosis. The mutation frequencies of the driver genes JAK2V617F, CALR, and MPL were 56.7% (240 cases), 17.0% (72 cases), and 5.4% (23 cases), respectively, while 21.3% (90 cases) of the patients had no driver gene mutations. After a median follow-up of 63.1 (95% <i>CI</i>: 60.9-68.5) months, 16 patients (3.8% ) died during the follow-up period, with an estimated 5-year OS rate of (97.4±0.8) %. IPSET, MIPSS-ET, AAA, and AAA+ scoring systems could effectively discriminate the OS of patients in different risk groups (all <i>P</i><0.001) ; the C-index for OS prediction was 0.756 for IPSET, 0.775 for MIPSS-ET, 0.762 for AAA, and 0.823 for AAA+, and the 5-year Brier scores were 0.023 5, 0.022 7, 0.023 2, and 0.022 6, respectively. Regarding risk restratification, the NRI of the AAA+ scoring system compared with the IPSET, MIPSS-ET, and AAA systems were 0.486, 0.352, and 0.268, respectively. The AAA+ system could accurately reclassify some patients who were categorized as low- or intermediate-risk by other systems into higher-risk groups, and the actual OS of these up-stratified patients was significantly inferior to that of the non-up-stratified group. <b>Conclusions:</b> The IPSET, MIPSS-ET, AAA, and AAA+ survival prognostic scoring systems are all effective for assessing survival risk in Chinese patients with ET. Among them, the AAA+ system exhibited optimal discrimination, calibration, and more accurate risk restratification efficacy in OS prediction, making it more suitable for individualized survival prognostic assessment in the Chinese ET population.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 6","pages":"549-556"},"PeriodicalIF":0.0,"publicationDate":"2026-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575519/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Risk factors and prognosis of disseminated intravascular coagulation in patients with non-M(3) acute myeloid leukemia].","authors":"M X Q Han, X Y Xu, H Wang, D P Wu, Y Han","doi":"10.3760/cma.j.cn121090-20251125-00548","DOIUrl":"10.3760/cma.j.cn121090-20251125-00548","url":null,"abstract":"<p><p>This study retrospectively analyzed 407 newly diagnosed patients with non-M(3) acute myeloid leukemia (AML) treated at the First Affiliated Hospital of Soochow University between 2016 and 2024. Based on the ISTH-2018 DIC score, patients were classified into a DIC group (<i>n</i>=109) and a non-DIC group (<i>n</i>=298), and their clinical characteristics and survival were compared. The results showed that white blood cell count, bone marrow blast percentage, alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase levels were significantly higher in the DIC group than in the non-DIC group (all <i>P</i><0.001). Molecular analysis indicated that NPM1, FLT3-ITD, and SETD2 mutations were significantly enriched in the DIC group (all <i>P</i><0.05). Multivariable logistic regression showed that a high white blood cell count, a high blast percentage, an elevated lactate dehydrogenase level, and NPM1 mutation were independent risk factors for DIC (all <i>P</i><0.05). Clinical outcome analysis showed that the DIC group had a higher incidence of early severe bleeding (<i>P</i><0.001) and a lower complete remission rate after first induction chemotherapy (<i>P</i><0.05). In the overall population, especially in the European LeukemiaNet (ELN) 2022 high-risk subgroup, overall survival (OS) was significantly worse in the DIC group than in the non-DIC group (<i>P</i><0.05). Multivariable Cox regression further confirmed that concomitant DIC, early severe bleeding, and older age were independent risk factors for OS in patients with non-M(3) AML (all <i>P</i><0.05). These findings suggest that DIC in non-M(3) AML is closely associated with a high tumor burden and specific molecular abnormalities and is accompanied by a higher risk of early bleeding and poorer survival outcomes. DIC may therefore represent a higher-risk clinical feature requiring enhanced early monitoring and risk-stratified management.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 6","pages":"576-581"},"PeriodicalIF":0.0,"publicationDate":"2026-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575516/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The prognostic value of IGHV gene segment usage in advanced-stage follicular lymphoma with bone marrow infiltration].","authors":"Y L Li, R Z Chen, N Chen, T L Qiu, H Y Shen, H Jin, C Qiao, H Y Zhu, L Fan, W Xu, J Y Li, W Y Shi, Y Miao, Y Xia","doi":"10.3760/cma.j.cn121090-20251207-00575","DOIUrl":"10.3760/cma.j.cn121090-20251207-00575","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the prognostic value of immunoglobulin heavy chain variable region (IGHV) gene segment usage characteristics in high-risk follicular lymphoma (FL) patients with bone marrow infiltration. <b>Methods:</b> The clinical data of 33 patients of FL with bone marrow infiltration diagnosed at Jiangsu Province Hospital from August 2017 to November 2024 were collected and retrospectively analyzed. <b>Results:</b> Among the 33 enrolled FL patients, 32 (97.0% ) had mutated IGHV, with a median germline identity of 90.7%. The IGHV3 family was predominant (23 cases, 69.7% ), with IGHV3-48 (9 cases, 27.3% ), IGHV3-23 (4 cases, 12.1% ), and IGHV3-66 (4 cases, 12.1% ) as the most frequent segments. Consistent with prior reports, the frequency of IGHV3-48 usage in our cohort (27.3% ) was higher than that observed in other B-cell lymphomas, including chronic lymphocytic leukemia (3.8% ), splenic marginal zone lymphoma (0), and Waldenström macroglobulinemia (2.2% ) (all <i>P</i> value<0.05). Univariate analysis showed that FL patients using the IGHV3-48 gene exhibited higher lactate dehydrogenase levels (66.7% <i>vs</i> 13.6% ; <i>OR</i>=12.7, 95% <i>CI</i>: 1.6-102.3, <i>P</i>=0.017) and a higher proportion of FLIPI-2 score ≥3 (88.9% <i>vs</i> 33.3% ; <i>OR</i>=15.0, 95% <i>CI</i>: 1.6-142.2, <i>P</i>=0.018). Furthermore, patients using the IGHV3-48 gene segment also demonstrated a trend toward an increased risk of disease progression within 12 months (POD12) (44.4% <i>vs</i> 12.5% ; <i>OR</i>=4.8, 95% <i>CI</i>: 0.8-28.9, <i>P</i>=0.087) . <b>Conclusion:</b> The usage of the IGHV3-48 gene may have certain reference value for early prognostic prediction in FL patients with bone marrow infiltration.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 6","pages":"557-563"},"PeriodicalIF":0.0,"publicationDate":"2026-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Construction of a methionine metabolism-related prognostic signature and the effect of targeting methionine metabolism on diffuse large B-cell lymphoma].","authors":"B Y Wang, M F Gu, J Y Li, Z J Wu","doi":"10.3760/cma.j.cn121090-20251219-00603","DOIUrl":"10.3760/cma.j.cn121090-20251219-00603","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To construct a prognostic risk model based on methionine metabolism-related genes in diffuse large B-cell lymphoma (DLBCL), investigate its prognostic significance, and clarify the regulatory role of abnormal methionine metabolism in DLBCL progression. &lt;b&gt;Methods:&lt;/b&gt; Clinical prognostic information and methionine metabolism-related gene expression data of patients with DLBCL were obtained from the GEO dataset GSE10846. Lasso regression and Cox regression analyses were performed to screen core prognostic genes and establish a risk model, which was further validated in GSE11318 and GSE181063 datasets. The potential biological functions were analyzed by using Gene Ontology, Kyoto Encyclopedia of Genes and Genomes pathway analysis, and Gene Set Enrichment Analysis. The DLBCL cell lines U2932 and SUDHL-4 were cultured in vitro and divided into the normal culture group (control group), methionine deprivation group, methionine deprivation + methionine supplementation group (methionine supplementation group), and methionine deprivation + S-adenosylmethionine (SAM) supplementation group (SAM supplementation group). Intracellular concentrations of methionine and SAM were detected by liquid chromatography-mass spectrometry. Cell proliferation and apoptosis were measured by using CCK-8 assay and flow cytometry, respectively. A U2932 cell-derived xenograft model was established in NOD-SCID mice, which were assigned to the control diet group (&lt;i&gt;n&lt;/i&gt;=5) and methionine-restricted diet group (&lt;i&gt;n&lt;/i&gt;=5), and tumor growth was monitored dynamically. &lt;b&gt;Results:&lt;/b&gt; Eight core genes were screened from 33 methionine metabolism-related genes to construct the prognostic risk model. Kaplan-Meier analysis in the training set revealed that overall survival was significantly shorter in the high-risk group than in the low-risk group (&lt;i&gt;HR&lt;/i&gt;=2.50, 95% &lt;i&gt;CI&lt;/i&gt;: 1.84-3.39, &lt;i&gt;P&lt;/i&gt;&lt;0.001). Stable prognostic performance was confirmed in two validation sets: GSE11318 (&lt;i&gt;HR&lt;/i&gt;=1.89, 95% &lt;i&gt;CI&lt;/i&gt;: 1.30-2.75, &lt;i&gt;P&lt;/i&gt;&lt;0.001) and GSE181063 (&lt;i&gt;HR&lt;/i&gt;=1.39, 95% &lt;i&gt;CI&lt;/i&gt;: 1.20-1.62, &lt;i&gt;P&lt;/i&gt;&lt;0.001). In vitro, compared with the normal culture group, the methionine deprivation group showed significantly decreased intracellular levels of methionine and SAM (both &lt;i&gt;P&lt;/i&gt;&lt;0.001), completely inhibited cell proliferation, and increased apoptosis (both &lt;i&gt;P&lt;/i&gt;&lt;0.001); compared with the methionine deprivation group, the methionine supplementation group and SAM supplementation group exhibited significantly restored apoptosis (all &lt;i&gt;P&lt;/i&gt; value &lt;0.001). In vivo, methionine restriction evidently reduced tumor volume [ (438.3±179.1) mm(3) &lt;i&gt;vs&lt;/i&gt; (1 451.0±464.9) mm(3), &lt;i&gt;P&lt;/i&gt;=0.002] and tumor weight [ (0.3±0.1) g &lt;i&gt;vs&lt;/i&gt; (1.1±0.4) g, &lt;i&gt;P&lt;/i&gt;=0.004] compared with the control diet. &lt;b&gt;Conclusion:&lt;/b&gt; The prognostic risk model based on methionine metabolism-related genes shows potential prognostic value for DLBCL. Abnormal methionine metabolism regulates","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 5","pages":"473-479"},"PeriodicalIF":0.0,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13416638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148397244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Application and challenges of the clinical decision support system in hematological diseases].","authors":"A Jia, L L Liu, S P Qin, X Y Zhao","doi":"10.3760/cma.j.cn121090-20251012-00460","DOIUrl":"10.3760/cma.j.cn121090-20251012-00460","url":null,"abstract":"<p><p>Hematological diseases, particularly hematological neoplasms, are highly heterogeneous, characterized by diverse clinical manifestations and complex biological features. Clinical Decision Support System (CDSS) is an auxiliary diagnosis and treatment system that integrates clinical data, medical expertise, and artificial intelligence (AI), which is expected to significantly improve the standardization, accuracy, and efficiency of diagnosis and treatment for hematological diseases and thereby improve prognosis. This review aimed to systematically summarize the application status of CDSS in hematological diseases, discuss its core value, analyze the current challenges, and outline future development. CDSS has potential in standardized diagnosis and treatment, accurate diagnosis and treatment, early prevention, and efficiency improvement of hematological diseases, including hematological neoplasms and bleeding and coagulation disorders. However, it faces many challenges, such as data processing, knowledge base construction and maintenance, model performance optimization, system integration, and a lack of evaluation criteria. In the future, CDSS is expected to integrate multicenter and multimodal data to enable precise, individualized, and whole-process hematological disease management.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 5","pages":"507-512"},"PeriodicalIF":0.0,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13416532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148398015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}